Cargando…

Unfavorable efficacy to (131)I ablation in BRAFV600E mutant papillary thyroid carcinoma with positive TgAb

The BRAFV600E mutation has shown a close relationship of aggressiveness in papillary thyroid carcinoma (PTC), while it remains unclear about its influence on the therapeutic response. As a common clinicopathologic risk factor, thyroglobulin antibody (TgAb) may have a correlation of prognosis in PTC....

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Na, Liang, Jun, Lin, Yan-Song
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5722572/ https://www.ncbi.nlm.nih.gov/pubmed/29228620 http://dx.doi.org/10.18632/oncotarget.22129

Ejemplares similares

Predictive Value of FNA-Tg and TgAb in Cervical Lymph Node Metastasis of Papillary Thyroid Carcinoma
por: Wu, Xiaoli, et al.
Publicado: (2022)

The influence of thyroid status, serum Tg, TSH, and TgAb on FNA‐Tg in cervical metastatic lymph nodes of papillary thyroid carcinoma
por: Sun, Jingjing, et al.
Publicado: (2021)

Serum thyroglobulin evaluation on LC-MS/MS and immunoassay in TgAb-positive patients with papillary thyroid carcinoma
por: Nishihara, Eijun, et al.
Publicado: (2021)

Diagnostic Performance of (18)F-FDG PET/CT in Papillary Thyroid Carcinoma with Negative (131)I-WBS at first Postablation, Negative Tg and Progressively Increased TgAb Level
por: Qiu, Zhong-Ling, et al.
Publicado: (2017)

Clinical impact of thyroglobulin (Tg) and Tg autoantibody (TgAb) measurements in needle washouts of neck lymph node biopsies in the management of patients with papillary thyroid carcinoma
por: Martins-Costa, M. Cecilia, et al.
Publicado: (2017)

Possible added value of thyroglobulin antibody (TgAb) testing in the evaluation of thyroidal status of subjects with overweight or obesity
por: Fierabracci, P., et al.
Publicado: (2022)

Stimulated thyroglobulin and pre-ablation antithyroglobulin antibody products can predict the response to radioiodine therapy of TgAb-positive differentiated thyroid cancer patients: a retrospective study
por: Han, Na, et al.
Publicado: (2023)

The clinical significance of BRAFV600E mutations in pediatric papillary thyroid carcinomas
por: Li, Yangsen, et al.
Publicado: (2022)

Prognostic Value of Basal Serum Thyroglobulin Levels, but Not Basal Antithyroglobulin Antibody (TgAb) Levels, in Patients with Differentiated Thyroid Cancer
por: Neshandar Asli, Isa, et al.
Publicado: (2014)

The Role of Thyroid Hormones and Autoantibodies in Metabolic Dysfunction Associated Fatty Liver Disease: TgAb May Be a Potential Protective Factor
por: Zhang, Xiaofu, et al.
Publicado: (2020)

Identification of R-Spondin Gene Signature Predictive of Metastatic Progression in BRAFV(600E)-Positive Papillary Thyroid Cancer
por: da Silva, Sabrina Daniela, et al.
Publicado: (2022)

Diagnostic Efficacy of BRAFV600E Immunocytochemistry in Thyroid Aspirates in Bethesda Category IV and Papillary Thyroid Carcinoma
por: Anand, Nidhi, et al.
Publicado: (2021)

Prevalence of BRAFV600 in glioma and use of BRAF Inhibitors in patients with BRAFV600 mutation-positive glioma: systematic review
por: Andrews, Lily J, et al.
Publicado: (2021)

BRAFV600E mutation is associated with aggressive features in papillary thyroid carcinomas ≤ 1.5 cm
por: Silver, Jennifer A., et al.
Publicado: (2021)

OR09-4 Novel Murine Models of BrafV600E driven Papillary Thyroid Cancer
por: Casado Medrano, Victoria, et al.
Publicado: (2022)

Positive BRAFV600E mutation of primary tumor influences radioiodine avidity but not prognosis of papillary thyroid cancer with lung metastases
por: Huang, Shuhui, et al.
Publicado: (2022)

Clinicopathological Characteristics of Papillary Thyroid Cancer in Children with Emphasis on Pubertal Status and Association with BRAFV600E Mutation
por: Poyrazoğlu, Şükran, et al.
Publicado: (2017)

Iodine nutritional status is not a direct factor in the prevalence of the BRAFV600E mutation in papillary thyroid cancer
por: Lin, Yan-Yu, et al.
Publicado: (2023)

Recurrent papillary craniopharyngioma with BRAFV600E mutation treated with neoadjuvant-targeted therapy
por: Rostami, Elham, et al.
Publicado: (2017)

Relation Between F-18 FDG Uptake of PET/CT and BRAFV600E Mutation in Papillary Thyroid Cancer
por: Yoon, Seokho, et al.
Publicado: (2015)

HER inhibitor promotes BRAF/MEK inhibitor-induced redifferentiation in papillary thyroid cancer harboring BRAFV600E
por: Cheng, Lingxiao, et al.
Publicado: (2017)

X-linked inhibitor of apoptosis protein (XIAP) predicts disease-free survival in BRAFV600E mutant papillary thyroid carcinoma in middle eastern patients
por: Parvathareddy, Sandeep Kumar, et al.
Publicado: (2022)

The Presence of Serum TgAb Suggests Lower Risks for Glucose and Lipid Metabolic Disorders in Euthyroid General Population From a National Survey
por: Zhang, Jinjia, et al.
Publicado: (2020)

Role of ultrasonographic features and quantified BRAFV600E mutation in lymph node metastasis in Chinese patients with papillary thyroid carcinoma
por: Guo, Liang, et al.
Publicado: (2019)

Detection of BRAFV600E in Liquid Biopsy from Patients with Papillary Thyroid Cancer Is Associated with Tumor Aggressiveness and Response to Therapy
por: Jensen, Kirk, et al.
Publicado: (2020)

Predicting BRAFV600E mutations in papillary thyroid carcinoma using six machine learning algorithms based on ultrasound elastography
por: Agyekum, Enock Adjei, et al.
Publicado: (2023)

The Transcription Factor ETV5 Mediates BRAFV600E-Induced Proliferation and TWIST1 Expression in Papillary Thyroid Cancer Cells()
por: Puli, Oorvashi Roy, et al.
Publicado: (2018)

BRAFV600E-Associated Gene Expression Profile: Early Changes in the Transcriptome, Based on a Transgenic Mouse Model of Papillary Thyroid Carcinoma
por: Rusinek, Dagmara, et al.
Publicado: (2015)

Impact of BRAFV600E Mutation on Event-Free Survival in Patients with Papillary Thyroid Carcinoma: A Retrospective Study in a Romanian Population
por: Nechifor-Boilă, Adela, et al.
Publicado: (2023)

Monitoring of Dabrafenib and Trametinib in Serum and Self-Sampled Capillary Blood in Patients with BRAFV600-Mutant Melanoma
por: Isberner, Nora, et al.
Publicado: (2022)

BRAFV600E and KIT immunoexpression in early-stage melanoma
por: Germano, Andressa, et al.
Publicado: (2019)

Sequence of therapies for advanced BRAFV600E/K melanoma
por: Gonzalez-Cao, Maria, et al.
Publicado: (2023)

Pluripotency markers are differentially induced by MEK inhibition in thyroid and melanoma BRAFV600E cell lines
por: Dorris, Emma R., et al.
Publicado: (2016)

The Relationship of TPOAb and TGAb with Risk of Thyroid Nodules: A Large Epidemiological Study
por: Xu, Weimin, et al.
Publicado: (2017)

mTORC1/autophagy-regulated MerTK in mutant BRAFV600 melanoma with acquired resistance to BRAF inhibition
por: Xue, Gongda, et al.
Publicado: (2017)

Profile of BRAFV600E, BRAFK601E, NRAS, HRAS, and KRAS Mutational Status, and Clinicopathological Characteristics of Papillary Thyroid Carcinoma in Indonesian National Referral Hospital
por: Harahap, Agnes Stephanie, et al.
Publicado: (2023)

Developing Models to Predict BRAFV600E and RAS Mutational Status in Papillary Thyroid Carcinoma Using Clinicopathological Features and pERK1/2 Immunohistochemistry Expression
por: Harahap, Agnes Stephanie, et al.
Publicado: (2023)

BRAFV600E Negatively Regulates the AKT Pathway in Melanoma Cell Lines
por: Chen, Brenden, et al.
Publicado: (2012)

Lack of BRAFV600E mutation in stage I and II of colorectal cancer
por: Molaei, Mahsa, et al.
Publicado: (2016)

Response of recurrent BRAFV600E mutated ganglioglioma to Vemurafenib as single agent
por: del Bufalo, Francesca, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_38n75drem0r06n8og35fefhcga